| Chrastina and Schnitzer;73 iodine-125 radiolabeling of silver nanoparticles
for in vivo SPECT imaging |
0.4–0.6 μCi/μg of 125I-AgNPs; no stability data |
RCY > 80% |
| Jeon et al.;61 an optimized protocol for the
efficient radiolabeling of gold nanoparticles
using a 125I-labeled azide prosthetic
group |
150 MBq no stability
data |
radiochemical yield (75 ± 10%, n = 8) and RCP ≥ 99% |
| Zhang et al.;72 synthesis and bioevaluation
of iodine-131 directly
labeled cyclic RGD-PEGylated gold nanorods
for tumor-targeted imaging |
stability in vitro with RCP of 97.79 ± 0.50% in PBS and 95.59 ± 0.73% in FBS at 48 h |
RCY [131I]GNR-PEG-cRGD = 64.54 ± 3.81%, RCP 98.17 ± 0.86% |
| Walsh;71 chemisorption of iodine-125 to gold nanoparticles
allows for real-time quantitation and
potential use in nanomedicine |
in three different buffers
for >100 days at 5 °C, >92%; 20 μCi |
RCP > 92% |
| Aries et al.;70 iodogen method on iodine-131 (131I) radiolabelling
of silver nanoparticle (AgNPs) as a new agent of molecular imaging |
5 days in room temperature RCP > 90% |
RCP 94.5 ± 0.21% |
| Mohammadi et al.;68 cellular uptake, imaging, and pathotoxicological
studies of novel Gd[III]-DO3A-butrol nanoformulation |
|
the concentration limit
of the noncytotoxic nanoformulation
is 2 × 5 μg/mL and cellular
uptake is 70% |
| Piccolo et al.;67 exploring cellular uptake, accumulation, and mechanism
of action of a cationic Ru-based nanosystem
in human preclinical models of breast cancer |
|
the highest cellular uptake is 80% |
| Xie et al.;74 131I-IITM and 211At-AITM: two novel small-molecule radiopharmaceuticals
targeting oncoprotein metabotropic glutamate receptor 1 |
RCY 42.7% stability >97% at 24 h |
the highest cellular uptake is 50–60% |
